WASHINGTON — U.S. health officials on Monday placed new restrictions on a permanent contraceptive implant that has been subject to reports of painful complications from thousands of women. But the metal implant, called Essure, will remain on the market.

The Food and Drug Administration said only women who read and have the opportunity to sign a brochure about the risks of the device will be able to receive the implant made by Bayer. The checklist of risks must also be signed by the woman’s doctor.

The new requirement comes almost two years after the FDA added its strongest warning to Essure, citing problems reported with the nickel-titanium implant. The agency also ordered Bayer to conduct a study of the device’s safety.


Patients have reported cases of pain, bleeding, allergic reactions and cases where the implant punctured the uterus or shifted out of place. Those reports are submitted to the FDA by patients, physicians and the manufacturer.

“Despite previous efforts to alert women to the potential complications of Essure, we know that some patients still aren’t receiving this important information,” said FDA Commissioner Scott Gottlieb, in a statement. “That is simply unacceptable.”

An agency spokeswoman said via email that the new requirements “ensure that the device continues to meet our standards for a reasonable assurance of safety and effectiveness.”

In a statement after the announcement, Bayer said it will continue to tell health care providers about “the importance of appropriately counseling each patient on the benefits and risks of Essure.”

Public health advocates questioned the FDA’s new requirement, suggesting patients may not read the lengthy brochure.

“How many people do you know who would carefully read a 22-page document before signing it?” said Diana Zuckerman, president of the National Center for Health Research, a consumer advocacy group. “In addition to being much too long and technical, the information provided will be confusing to many consumers.”

Bayer received FDA approval to sell Essure in 2002 and promoted the product to women as the only non-surgical option for permanent birth control. Essure consists of two nickel-titanium coils inserted into the fallopian tubes, where they spur the growth of scar tissue that blocks sperm from fertilizing a woman’s eggs.

Because of the reported complaints, Bayer was ordered to conduct a 2,000-patient study in 2016. Although the company is making “adequate progress,” the FDA said Monday that it will require additional study sites to enroll more patients in the study. The agency notes that sales of Essure have fallen 70 percent since the previous FDA restrictions were announced.

Bayer faces lawsuits from approximately 16,000 U.S. women who have received Essure, according to the German conglomerate’s latest annual report. While the company is insured against product liability lawsuits, the Bayer notes that the claims “exceed the available insurance coverage.” The company stopped selling Essure outside the U.S. last year.

Last month, the FDA reported that it had received 12,000 reports last year about problems with Essure, 90 percent of which involved attempts to remove the device. The agency noted that most of the new reports came from attorneys representing patients suing Bayer.



— Matthew Perrone

Leave a Comment

Please enter your name.
Please enter a comment.

  • The FDA, just another government scam to pick the pockets of the American taxpayers. This article proves it’s all about the almighty dollar and not the people’s health and well-being. What about making Bayer responsible for all the women who received the implants before the additional reading material and now are suffering from complications/ side effects and no doctor who is willing to attempt the removal related to the high risks of complications. When and how do they get relief? The FDA should be ashamed of their actions, or lack there of, in this debacle.

  • With the info about ~50% ovarian CA prevention from complete bilateral salpingectomy, I could see this procedure becoming more and more obsolete, even without all of the complication stuff. But it is a cash cow for outpatient offices, which makes it popular.

  • Hard to believe any implantable device which has been verified to puncture the uterus and migrate is still being allowed on the market. It’s not OK for any implant to destroy a uterus and deny anyone the ability to conceive. It’s not OK for any woman to have an implantable device which migrates from original site. Surgery, adhesions, pelvic pain is the pathway when this occurs. I find it unbelievable this device has not been immediately banned from the market. Sounds like a version of the Fall in shield to me…and look how long before THAT nightmare implant took to finally be banned from the market: Deaths, PID, total hysterctomies, pregnancies with offspring born with the shield implanted in the newborns shoulder….I don’t care how many gyns “sign off” a checklist for continued use of this implant. If I were the pt.,I’d run out the guns office and know I was in the wrong place with a M.D. worrying about his/her cash cow, NOT my health and well being!

    • Sorry, my comment above was changed from intended wording of “DALKON SHIELD” to “fall in.” So much for the notso smart phone. Tried to edit and correct the mistake, no method to accomplish this, hence my follow up comment for correction purposes here.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy